Tag Archives: conference

RSC Fragments 2024

I attended RSC Fragments 2024 (Hinxton, 4–5 March 2024), a conference dedicated to fragment-based drug discovery. The various talks were really good, because they gave overviews of projects involving teams across long stretches of time. As a result there were no slides discussing wet lab protocol optimisations and not a single Western blot was seen. The focus was primarily either illustrating a discovery platform or recounting a declassified campaign. The latter were interesting, although I’d admit I wish there had been more talk of organic chemistry —there was not a single moan/gloat about a yield. This top-down focus was nice as topics kept overlapping, namely:

  • Target choice,
  • covalents,
  • molecular glues,
  • whether to escape Flatland,
  • thermodynamics, and
  • cryptic pockets
Continue reading →

Festival of Biologics 2022 – November 2-4 Basel, Switzerland

In November I attended the Festival of Biologics (FoB) 2022 conference in Basel, Switzerland. Originally a set of different conferences (now called agendas) that has merged into a single conference, FoB focuses on anything related to biologics. One of the agendas is an antibody specific agenda, derived from the former European Antibody Congress. This year the antibodies agenda had more than 100 talks across multiple tracks, covering many different aspects of using antibodies as therapeutics, making it an exciting conference for an antibody enthusiast. However, while FoB does include talks on machine learning and bioinformatics, most are focused solely on experimental work. Another drawback is that the majority of the talks are by industry, with the few academic speakers almost all also representing a company. This meant that of the few talks about computational methods and tools for protein design, most felt more like a commercial rather than a research presentation. Nonetheless, FoB is still an interesting conference to attend when you are working on applied research for antibody therapeutics. It is an amazing opportunity to hear about which antibody specific problems companies are trying to overcome, which are deemed solved and which are the future problems to solve.

Continue reading →

Thinking of going to a conference

As so many members of the group have never attended an in-person conference, I thought it might be worth answering the question “why do people attend conferences?”

First- up, we should remember that flying around the world is not a zero cost to the planet, so all of us lucky enough to be able to travel should think hard every time before we choose to do so.

This means it’s really important to make sure that we know why we are going to any conference and maximise the benefits from attendance. Below are a few things to think about in terms of why you attend a conference and what to do when you are there, but this is definitely not a complete list, more a starter for four.

Continue reading →

Vaccines and vino

Recently, I was fortunate enough to attend and present at GSK’s PhD and Postdoc workshop in Siena, Italy. The workshop spanned two days and I had a brilliant time there – Siena itself is beautiful, I ate fantastic food, and I learnt a huge amount about all stages of vaccine production.

Unfortunately, due to confidentiality, I can’t go into great detail about others’ current research, however I have provided a short overview of the five main areas the workshop focused on below.

Continue reading →

Antibody Engineering and Therapeutics Conference

I was invited to speak at the Antibody Engineering and Therapeutics Conference (presenting mine and Matt’s recently published epitope profiling paper), in San Diego (December 12th – 16th). Unfortunately, the pandemic had other ideas so I decided not to travel but luckily the conference was hybrid. 

The conference included 1 day of pre-conference workshops and 4 days of presentations from academic and industry, with livestreaming of the initial keynotes (including one from Charlotte). Remaining talks were recorded and made available after the conference. I’ve highlighted a few of my favourite talks and conference themes, with links to papers where available.

Naturally, a lot of the presented research related to covid-19. I was speaking in the ‘Antibody Repertoires and Covid-19’ session, where there were interesting presentations from Professor Eline Luning Prak from the University of Pennsylvania and Elaine Chen from Vanderbilt University analysing antibody responses in covid-recovered individuals, and comparing vaccine responses in covid-recovered vs covid-naiive individuals. Other talks around SARS-CoV-2 vaccines included Dr Laura Walker from Adimab/Adagio Therapeutics comparing BCR repertoire responses to different types of vaccinations, and the effect of using different booster types.

Continue reading →

Highlights from the European Antibody Congress 2021

Last month, I was fortunate enough to be able to attend (in person!) and present at the Festival of Biologics European Antibody Congress (9-11 November, 2021) in Basel, Switzerland. The Festival of Biologics is an annual conference, which brings together researchers from industry and academia. It was an excellent opportunity to learn about exciting research and meet people working in the antibody development field.

Here are some of my highlights from the European Antibody Congress, with a focus on antibody design and engineering:

Continue reading →

AIRR Community Meeting V – December 2020

We attended the virtual Adaptive Immune Receptor Repertoire (AIRR) Community Meeting in early December. The three day conference is usually held every 18 months and covered a range of research talks, software demonstrations and poster presentations on the latest TCR and BCR (antibody) research. While we missed certain elements that were present at the last AIRR community meeting (namely focaccia), it was a really interesting meeting with technology all running very smoothly.

Given our current research on SARS-CoV-2 antibodies, we particularly enjoyed the work presented by Armita Nourmohammad from the University of Washington on “Dynamics of BCR in Covid”, based on the preprint on medRxiv. The research identified 34 significantly expanded rare clonal lineages shared among patients with SARS-CoV-2, which are potential candidates for covid response. In particular, the analysis includes an assessment of whether an antibody sequence identified in different individuals (known as a shared or public sequence) is likely to be found due to inherent biases in antibody recombination. Shared antibody sequences which are calculated as  unlikely to be shared are potentially a response to a shared exposure such as SARS-CoV2, rather than randomly found in the antibody repertoire. In this way, Nourmohammed and colleagues identified ‘rare’ antibodies which were identified in more individuals than would statistically be expected, and therefore might be worthy of further experimental analysis.

A theme common across a short talk and poster by Hadas Neuman (Bar-Ilan) and a poster by Kenneth Hoehn (Yale), was class-switching dynamics revealed by phylogenetic inference (from IgM to IgA in the human gut in the former, and IgE and IgG4 in a paediatric patient with peanut allergy in the latter). Kenneth Hoehn’s poster also looked at B-cell differentiation during HIV infection – this can all be read about in this preprint. The methods developed in the paper for discrete trait analysis of differentiation, isotype switching and B-cell migration are implemented in the new R package dowser (https://bitbucket.org/kleinstein/dowser) which is part of the Immcantation suite (http://immcantation.org).

It was also really nice to see evidence of the burgeoning use of single-cell sequencing for immune repertoire profiling, with posters by Igor Snapkov (UiO), Indu Khatri (Leiden University Medical Centre), Nick Borcherding (Washington University in St. Louis) all using single-cell technologies, and a talk by Ivelin Georgiev on LIBRA-seq. 

If you missed the conference and have had your interest piqued, some of the conference talks are available at the AIRRC youtube channel.

We look forward to AIRRC6, Dec 7 – 11, 2021!

Sarah and Eve

NeurIPS 2020: Chemistry / Biology papers

Another blog post, another look at accepted papers for a major ML conference. NeurIPS joins the other major machine learning conferences (and others) in moving virtual this year, running from 6th – 12th December 2020. In a continuation of past posts (ICML 2020, NeurIPS 2019), I will highlight several of potential interest to the chem-/bio-informatics communities

The list of accepted papers can be found here, with 1,903 papers accepted out of 9,467 submissions (20% acceptance rate).

In addition to the main conference, there are several workshops highly related to the type of research undertaken in OPIG: Machine Learning in Structural Biology and Machine Learning for Molecules.

The usual caveat: given the large number of papers, these were selected either by “accident” (i.e. I stumbled across them in one way or another) or through a basic search (e.g. Ctrl+f “molecule”). If you find any I have missed, please reach out and I will update accordingly.

Continue reading →

Learning from Biased Datasets

Both the beauty and the downfall of learning-based methods is that the data used for training will largely determine the quality of any model or system.

While there have been numerous algorithmic advances in recent years, the most successful applications of machine learning have been in areas where either (i) you can generate your own data in a fully understood environment (e.g. AlphaGo/AlphaZero), or (ii) data is so abundant that you’re essentially training on “everything” (e.g. GPT2/3, CNNs trained on ImageNet).

This covers only a narrow range of applications, with most data not falling into one of these two categories. Unfortunately, when this is true (and even sometimes when you are in one of those rare cases) your data is almost certainly biased – you just may or may not know it.

Continue reading →

ICML 2020: Chemistry / Biology papers

ICML is one of the largest machine learning conferences and, like many other conferences this year, is running virtually from 12th – 18th July.

The list of accepted papers can be found here, with 1,088 papers accepted out of 4,990 submissions (22% acceptance rate). Similar to my post on NeurIPS 2019 papers, I will highlight several of potential interest to the chem-/bio-informatics communities. As before, given the large number of papers, these were selected either by “accident” (i.e. I stumbled across them in one way or another) or through a basic search (e.g. Ctrl+f “molecule”).

Continue reading →